The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoption of rapid molecular diagnostics and blood culture testing. North America leads the market, with significant contributions from the U.S., while Asia Pacific is the fastest-growing region due to investments in infection control and antimicrobial resistance awareness. Innovations like AI-enabled monitoring and multiplex PCR are enhancing early detection and treatment, supporting better patient outcomes and antimicrobial stewardship programs worldwide.
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The cutaneous lupus erythematosus (CLE) market is projected to expand at an 8% compound annual growth rate through 2036, driven by increased disease awareness, better diagnostics, and a focus on autoimmune disorders. New targeted therapies and biolog...
